Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: The AMANDHA study

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 10, 2008, Pages 1347-1355

  Martinez Martin, Francisco Javier ^a   Saiz Satjes, Margarita ^b  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b CAP Rambla   (Spain)

Author keywords

Amlodipine; Diabetes; Hypertension; Manidipine; Microalbuminuria

Indexed keywords

ALBUMIN; AMLODIPINE; MANIDIPINE; METADRENALIN; NORMETADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; ORTHOSTATIC HYPOTENSION; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; AGED; ALBUMINURIA; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ALBUMINURIA; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 59049088101     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.10.1347     Document Type: Article

References (40)

1. Dobesh PP. Managing hypertension in patients with Type 2 diabetes mellitus. Am. J. Health. Syst. Pharm. 63(12), 1140-1149 (2006).
2. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M, Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med. Clin. (Barc). 124(16), 606-612 (2005).
3. de Pablos-Velasco PL, Martínez-Martín FJ, Molero R et al. Patterns of prescription of hypoglycaemic drugs in Gran Canaria (Canary Islands, Spain) and estimation of the prevalence of diabetes mellitus. Diabetes Metab. 31(5), 457-462 (2005).
4. Wild S, Roglic G, Green A et al. Global prevalence of diabetes; estimates for the year 2000 and projections for 2030. Diabetes Care 21(5), 1047-1053 (2004).
5. Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis, prevention and treatment. Clin. Exp. Hypertens. 26(7-8), 621-628 (2004).
6. Stratton IM, Cull CA, Adler AI et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49(8), 1761-1769 (2006).
7. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. [Errata in J. Hypertens. 21, 2203-2204 (2003) and J. Hypertens. 22, 435 (2004)] J. Hypertens. 21(6), 1011-1053 (2003).
8. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
9. Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). [Erratum in J. Hypertens. 25, 1749 (2007)] J. Hypertens. 25(9), 1105-1187 (2007).
10. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (9395), 1527-1535 (2003).
11. Franklin SS, Neutel JM, Initial combination therapy for rapid and effective control of moderate and severe hypertension. J. Hum. Hypertens. DOI:10.1038/jhh.2008.72 (Epub ahead of print) (2008).
12. McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can. J. Cardiol. 22(10), 855-860 (2006).
13. Banegas JR, Segura J, Ruilope LM et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 43(6), 1338-1344 (2004).
14. Weir MR. Microalbuminuria in Type 2 diabetics: an important, overlooked cardiovascular risk factor. J. Clin. Hypertens. 6(3), 134-141 (2004).
15. Tobe SW, McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. Can. Med. Assoc. J. 167(5), 499-503 (2002).
16. Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 65(Suppl. 2), 1-10 (2005).
17. Hirakata H, Iino K, Ishida I et al. Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus. Blood Press. Suppl. 3, 124-129 (1992).
18. Martínez Martín FJ. Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine. Nefrologia 27(Suppl. 6), 26-35 (2007).
19. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1(2), 113-119 (1992).
20. McInnes GT. Antihypertensive drugs in combination: additive or greater than additive? J. Hum. Hypertens. 21(12), 914-916 (2007).
21. Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin - angiotensin system: a rational and effective means for treating hypertension. J. Renin Angiotensin Aldosterone Syst. 9(1), 1-9 (2008).
22. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Rep. 4(6), 479-482 (2002).
23. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 340(9), 677-684 (1999).
24. Robles NR, Ocón J, Gómez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail. 27(1), 73-80 (2005).
25. Agodoa LY, Appel L, Bakris GL et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285(21), 2719-2728 (2001).
26. Sakamaki Y, Sasamura H, Ikeda S et al. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens. Res. 29(5), 333-338 (2006).
27. Fogari R, Mugellini A, Zoppi A et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur. J. Clin. Pharmacol. 61(7), 483-490 (2005).
28. + channel subtypes and pharmacology in the kidney. Circ. Res. 100(3), 342-353 (2007).
29. Roca-Cusachs A, Schmieder RE, Triposkiadis F et al. MORE Study Group. Efficacy of manidipine/delapril versus losartan/ hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J. Hypertens. 26(4), 813-818 (2008).
30. Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Rev. Cardiovasc. Ther. 5(2), 147-159 (2007).
31. Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J. Hum. Hypertens. 18(10), 687-691 (2004).
32. Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with Type 2 diabetes mellitus. Hypertens. Res. 31(1), 43-50 (2008).
33. Otero ML, Claros NM; Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and Type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin. Ther. 27(2), 166-173 (2005).
34. Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J. Cardiovasc. Pharmacol. 38(4), 642-650 (2001).
35. Payeras AC, Sladek K, Lembo G, Alberici M. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hype rtension: MAISH study. Clin. Drug Investig. 27(9), 623-632 (2007).
36. Mulè G, Nardi E, Cottone S et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am. J. Hypertens. 20(2), 197-203 (2007).
37. Mazza A, Zamboni S, Tikhonoff V et al. Pulse hypertension: a new component of the metabolic syndrome in elderly women? J. Hum. Hypertens. 21(12), 934-941 (2007).
38. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am. J. Cardiovasc. Drugs 7(6), 413-422 (2007).
39. Peng RD, Dominici F, Zeger SL. Reproducible epidemiologic research. Am. J. Epidemiol. 163(9), 783-789 (2006).
40. Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail. 25(5), 6818-6819 (2003).